Adaptive announced today that it has entered into a collaboration agreement with Bristol-Myers Squibb for the discovery of immunological biomarkers in oncology. Under the collaboration, Adaptive will use its proprietary immune profiling assay, immunoSEQ, to identify potential biomarkers that may inform about drug response.
Xconomy Seattle’s biotech conference, “Biotech in the Belt-Tightening Era,” held on April 9 featured many biotech industry leaders including Adaptive’s CEO Chad Robins. The conference dealt with the issue of rising healthcare costs and its impact on biotech companies and their ability to fund research for new drugs and diagnostics.
The April 11th issue of Nature magazine featured an article highlighting the importance of finding immunological markers for immunotherapy drugs and cell therapy approaches for cancer.
Adaptive received extensive coverage in the March issue of Nature Biotechnology as the publication covered personalized, sequencing-based immune profiling startups. The article details at length the science behind next-generation sequencing and how Adaptive’s assays can be used for, among other things, diagnosing lingering leukemia and lymphoma in patients.
On March 27, the New England Journal of Medicine published an article that highlights the clinical relevance of MRD monitoring by Next Generation Sequencing and its potential superiority to flow cytometry – concluding a wave of impactful articles this month supporting the launch of Adaptive’s clonoSEQ MRD technology.
Adaptive selected today four recipients to receive its Young Investigator Award for February. Winners will receive a $5,000 grant to use towards the purchase of immunoSEQ assays as part of their research in a variety of fields, such as immunology.
Scientists at Adaptive have published a paper in the upcoming edition of the Journal of Immunological Methods that demonstrates a new method for determining the relative proportions of CD4+ and CD8+ T cells.
Adaptive announced today that Robert Hershberg, M.D., Ph.D., has joined the company’s board of directors. Dr. Hershberg will work closely with the board and management team to focus on corporate strategy and clinical development.
Luke Timmerman, National Biotech Editor of Xconomy, attended the American Society of Hematology (ASH) meeting in Atlanta, GA, last month, and wrote Adaptive has “emerged on the national stage with valuable new approaches to diagnosis and disease monitoring.”
Adaptive today introduced clonoSEQ, a clinical assay to measure minimal residual disease (MRD) in a range of blood-based cancers that is significantly more sensitive than today’s most common pathology tests. clonoSEQ will be available for widespread clinical use by mid-2013.
1551 Eastlake Ave E, Suite 200
Seattle WA 98102
(855) 466-8667 (toll free)
© 2013 Copyright. Adaptive Biotechnologies LLC. All rights reserved.